...searches for a successor, Harry Welten will serve as interim CFO. He was CFO of Kuros...

...series A round from Sofinnova and venBio (see BioCentury, Aug. 17, 2015) . Chris Lieu CMP-001 Checkmate Pharmaceuticals Inc. Kuros...

...Cytos Biotechnology AG . Kuros Biosurgery AG reverse-merged with Cytos Biotechnology AG in December 2015 to form Kuros...

...Arbutus terminated a deal with Kuros, returning to Kuros worldwide rights to its virus-like particle (VLP...
...did not support further development. ARB-1598 is an agonist of toll-like receptor 9 (TLR9) . Kuros...
...that there are no financial terms associated with the termination (see BioCentury, Jan. 12, 2015). Kuros...

...the anti-PD-1 can work," Krieg said. Checkmate has the CpG DNA oligo CMP-001 partnered with Kuros...
...Inc. (NASDAQ:ADRO), Berkeley, Calif. Checkmate Pharmaceuticals Inc., Cambridge, Mass. Dynavax Technologies Corp. (NASDAQ:DVAX), Berkeley, Calif. Kuros...

...its capital to nine companies including immuno-oncology play Nouscom AG (Basel, Switzerland) and musculoskeletal company Kuros...

...$52.0 Heart Metabolics Ltd. Repurposed generic drug perhexiline for hypertrophic cardiomyopathy 4/17/14 Series A $20.0 Kuros...

...already made five investments from the fund, including investments in tissue repair and regeneration company Kuros Biosurgery AG...

...entity will be named Kuros Biosciences AG and focus on tissue repair and regeneration. Existing Kuros...
...shareholders will own about 80% of the company, and Cytos shareholders will hold the balance. Kuros’...
...IIb allergic asthma trial (see BioCentury, May 12, 2014). Cytos Biotechnology AG (SIX:CYTN), Schlieren, Switzerland Kuros Biosurgery AG...

...reverse merger with Cytos Biotechnology AG (SIX:CYTN). The combined entity will be Kuros Biosciences AG. Kuros'...
...will lead the merged company. Cytos Chairman and CEO Christian Itin will be chairman. Existing Kuros...